肝胆期磁共振对比剂摄取作为可切除肝细胞癌病理侵袭性特征及无复发生存期降低的预测生物标志物:与双示踪剂18F-FDG和18F-FCH PET/CT的比较
本回顾性研究纳入32例患者的35个手术证实肝细胞癌,比较钆贝葡胺增强MRI肝胆期肿瘤强化定量分析(LLCER)与双示踪剂18F-FDG及18F-FCH PET/CT预测病理侵袭性特征和RFS的表现。LLCER识别侵袭性HCC的AUROC为0.92,与18F-FDG SUVT/L的0.89无显著差异(p=0.70),优于18F-FCH SUVT/L的0.64(p=0.035);LLCER是多变量Cox分析中RFS的独立预测因子(HR 0.91,95%CI 0.84–0.99,p=0.022)。
要点
- LLCER识别侵袭性HCC的AUROC为0.92(95%CI 0.78–0.98),与18F-FDG SUVT/L的0.89无显著差异(p=0.70)。
- LLCER≤-4.72%预测中-低分化(敏感度100%、特异度92.9%)和MVI(敏感度93.3%、特异度60%)。
- LLCER≤-4.72%的患者术后RFS显著差于LLCER>-4.72%者(p=0.030)。
核心结论
- 钆贝葡胺注射后肝胆期肿瘤强化可能有助于识别侵袭性HCC病理特征及术后RFS降低的患者。
研究设计与样本
- 回顾性、IRB批准研究,纳入32例患者共35个手术证实HCC;所有患者术前2个月内行含延迟肝胆期的钆贝葡胺增强MRI和18F-FDG PET/CT,29/32例加行18F-FCH PET/CT。
关键影像表现/征象
- 计算每个病灶的MRI肝胆期病灶-肝对比强化比(LLCER)及两种示踪剂的SUVmax肿瘤-肝比值(SUVT/L)。
- 以AUROC曲线比较各指标预测病理侵袭性特征(组织学分级和微血管侵犯MVI)的价值。
- 以Cox回归模型分析各指标对RFS的预测价值。
诊断标准与关键数值
- LLCER识别侵袭性HCC的AUROC为0.92(95%CI 0.78–0.98)。
- 18F-FDG SUVT/L识别侵袭性HCC的AUROC为0.89(95%CI 0.74–0.97),与LLCER比较p=0.70。
- 18F-FCH SUVT/L识别侵袭性HCC的AUROC为0.64(95%CI 0.45–0.80),与LLCER比较p=0.035。
- LLCER≤-4.72%预测中-低分化:敏感度100%、特异度92.9%;预测MVI:敏感度93.3%、特异度60%。
- 多变量Cox回归中LLCER为RFS独立预测因子:HR 0.91(95%CI 0.84–0.99),p=0.022。
临床应用与阅片要点
- 作者在要点中提出,含延迟肝胆期图像的钆贝葡胺增强MRI可作为可切除HCC患者术前检查的一部分(may be suggested)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare the performance of the quantitative analysis of the hepatobiliary phase (HBP) tumor enhancement in gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI and of dual-tracer 18F-FDG and 18F-fluorocholine (FCH) PET/CT for the prediction of tumor aggressiveness and recurrence-free survival (RFS) in resectable hepatocellular carcinoma (HCC).
METHODS: This retrospective, IRB approved study included 32 patients with 35 surgically proven HCCs. All patients underwent Gd-BOPTA-enhanced MRI including delayed HBP images, 18F-FDG PET/CT, and (for 29/32 patients) 18F-FCH PET/CT during the 2 months prior to surgery. For each lesion, the lesion-to-liver contrast enhancement ratio (LLCER) on MRI HBP images and the SUVmax tumor-to-liver ratio (SUVT/L) for both tracers were calculated. Their predictive value for aggressive pathological features-including the histological grade and microvascular invasion (MVI)-and RFS were analyzed and compared using area under receiver operating characteristic (AUROC) curves and Cox regression models, respectively.
RESULTS: The AUROCs for the identification of aggressive HCCs on pathology with LLCER, 18F-FDG SUVT/L, and 18F-FCH SUVT/L were 0.92 (95% CI 0.78, 0.98), 0.89 (95% CI 0.74, 0.97; p = 0.70), and 0.64 (95% CI 0.45, 0.80; p = 0.035). At multivariate Cox regression analysis, LLCER was identified as an independent predictor of RFS (HR (95% CI) = 0.91 (0.84, 0.99), p = 0.022). LLCER - 4.72% or less also accurately predicted moderate-poor differentiation grade (Se = 100%, Sp = 92.9%) and MVI (Se = 93.3%, Sp = 60%) and identified patients with poor RFS after surgical resection (p = 0.030).
CONCLUSIONS: HBP tumor enhancement after Gd-BOPTA injection may help identify aggressive HCC pathological features, and patients with reduced recurrence-free survival after surgical resection.
KEY POINTS: • In patients with resectable HCC, the quantitative analysis of the HBP tumor enhancement in Gd-BOPTA-enhanced MRI (LLCER) accurately identifies moderately-poorly differentiated and/or MVI-positive HCCs. • After surgical resection for HCC, patients with LLCER - 4.72% or less had significantly poorer recurrence-free survival than patients with LLCER superior to - 4.72%. • Gd-BOPTA-enhanced MRI with delayed HBP images may be suggested as part of pre-surgery workup in patients with resectable HCC.
引用
- Mulé S, Chalaye J, Legou F, et al. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT. Eur Radiol. 2020. PMID: 32405753. doi:10.1007/s00330-020-06923-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。